{
    "nct_id": "NCT04022239",
    "official_title": "Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis",
    "inclusion_criteria": "* Patient with hematologic malignancies.\n* Donor: Matched sibling, matched unrelated, mismatched or haploidentical\n* Zubrod performance 0 to 2 or Karnofsky of at least 60.\n* Adequate organ function at time of study entry:\n\n  1. Creatinine less than or equal to 1.6 mg/dL and creatinine clearance >/= 30 ml/min. Creatinine clearance will be calculated using the Cockcroft-Gault equation\n  2. Total bilirubin less than < 1.5 x UNL\n  3. SGPT < 2.5 x ULN\n  4. Ejection fraction >/= 40%\n  5. FEV1, FVC and DLCO >/= 40%\n* Female patients of childbearing potential must agree to use an effective method of birth control while on study and for 6 months after the last dose of bendamustine. Male patients with female partners of childbearing potential must agree to use an effective method of birth control while on study and for 3 months after the last dose of bendamustine.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Pregnant or nursing women.\n* Known to be HIV positive\n* Active and uncontrolled disease/infection\n* Unable or unwilling to sign consent\n* Current active hepatic or biliary disease (with exception of Gilbert's syndrome)\n* Active hepatitis B or C.\n* Toxicities (grade > 1) unresolved from prior treatment (including chemotherapy, targeted therapy, immunotherapy, experimental agents radiation, or surgery.\n* Patients with standard risk acute leukemia in first complete remission and patients with chronic myeloid leukemia in first chronic will be excluded during escalated phase.",
    "miscellaneous_criteria": ""
}